Editas Medicine to Present New Preclinical Data Demonstrating Progress of EDIT-401 as Potential Treatment for Hyperlipidemia at Upcoming Scientific Conferences

Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company focused on developing transformative medicines for serious diseases, today announced that five abstracts have been accepted for ...

I went to an advanced high-school personal-finance class. Here's what I learned.

Huntington High School teacher Bryan Outsen (second from left) with students from his Advanced Placement Business With Personal Finance class. If you had $1,000 that you wanted to save for a special ...

NFL draft grades: Ranking all 32 teams' 2026 classes, with lowly Jets earning an A+

With the 2026 NFL draft complete, it's time to hand out grades. Which teams topped our ranking of the best team classes, and ...

Mercedes all-new C-Class electric sedan is a rolling tech demo with hyperscreens

Inside, the C-Class EV centers on large digital displays and interface design. A full-width digital layout dominates the ...
Style Weekly

Out of the Shadows

American-born Abstract Expressionist Amaranth Ehrenhalt’s painting, “Jump In and Move Around” is a cacophony of bright colors ...
The Nation

Revisiting the Advent of the Abstract

A recent gallery exhibition on abstract art and self-taught artists proposes a new story for the rise of abstraction.

Moleculin Announces Abstract Accepted for Poster Presentation at the 2026 ASCO Annual Meeting

Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), today announced that an abstract highlighting data on its lead drug candidate, annamycin, has been accepted for poster ...
The New York Times

In N.Y.C. Classes, Teachers Can Use A.I. to Plan but Not to Assign Grades

The largest school system in the United States released its first guide on how teachers can incorporate artificial intelligence into their work and schools. By Matthew Haag In New York City schools, ...
manilatimes

Prelude Therapeutics Announces Acceptance of Preclinical Abstract for PRT13722, a First-in-Class Oral KAT6A Selective Degrader at the 2026 AACR Annual Meeting

WILMINGTON, Del., March 17, 2026 (GLOBE NEWSWIRE)-- Prelude Therapeutics Incorporated (Nasdaq: PRLD), a precision oncology company, today announced that a poster with preclinical data on the Company’s ...